EUROPEAN BIOTECHNOLOGY | The UK government’s 5-year plan to tackle antimicrobial resistance has ambitious goals and is a positive first step forward in establishing a multinational effort to change the way antibiotic research is rewards and antibiotics are paid for. The plan announced a new model in which drug developers would be paid based on how valuable the medicines are to the patients and the health system, rather than on volume sold. The new model follows calls by DRIVE-AB and others for changes in the way antibiotic research is funded and the way antibiotics are paid for.